

Stockholm, August 24, 2009

Regarding Trade in SCN Shares on NGM Equity

As previously communicated, Scandinavian Clinical Nutrition AB (SCN) has applied for and been granted de-listing from Oslo Axess in Norway. From September 18 onwards, the SCN share will therefore only be traded on NGM Equity in Sweden, which may bring about certain changes for shareholders whose shares are registered in VPS in Norway.

On August 18, 2009, SCN and Oslo Börs communicated that Oslo Börs had decided to approve SCN's application regarding de-listing from Oslo Axess. The last day of trade on Oslo Axess will be September 17, 2009. From September 18 2009 onwards, trade in the SCN share will only take place on NGM Equity in Sweden. This means that shareholders in SCN whose shares are registered in VPS in Norway may have to take certain measures.

Today, the majority of the shares in SCN are registered in Euroclear (formerly VPC) in Sweden. SCN's objective is to have all the shares registered in Sweden, in line with the company's constant striving to decrease administration and connected costs. Trade on NGM Equity normally takes place through a bank or custodian. Depending on which bank the shareholder has, shareholders whose shares are registered on Norwegian VPS accounts may have to open a depot in Sweden, or to move the shares to a Swedish VP account. SCN's recommendation to shareholders whose shares are registered in VPS is to contact their custodian/bank about this. Trade in shares across borders often incurs an extra cost.

The decision to apply for de-listing from Oslo Axess was made by an extraordinary general meeting in SCN on May 20, 2009. The Board's motives for the proposal were in short the following:

- trade in the company's shares on Oslo Axess has been very limited
- the spread of the shares in Norway is very limited
- a double stock exchange listing requires significant resources, both in terms of costs and workload
- the company has its domicile and headquarters in Stockholm and its home state in Sweden
- the majority of the shareholders and other interested parties in the company are Swedish
- the main part of the trade in the share takes place on NGM Equity
- since the listing on NGM is proposed to remain, the interests of minority shareholders will still be accommodated

With the above in mind, the Board could not defend that a company of SCN's size carries the costs for a double stock exchange listing, and therefore proposed the EGM to authorize the Board to apply for de-listing of the company's shares from Oslo Axess, and to take the measures necessary to carry this out. The EGM decided in accordance with the Board's proposal.

For more information, please contact:

Ørnulf Samdal, os@scnutrition.com, +47 930 14 700
Nils Stiernstedt, ns@scnutrition.com, +46 705 50 73 23

Scandinavian Clinical Nutrition i Sverige AB (publ) works in R&D and distribution of clinically tested, scientifically documented products within the field of nutrition (nutraceuticals). Established in 2006, SCN maintains a product portfolio with established trademarks, such as thin400, CUUR, Coldizin, Immulina, Membra7 and Ledactin. Core competence and strategic alliances, within both R&D and sales, in combination with innovative and clinically proven products, create good conditions for profitable growth both in Sweden and internationally. The shares of SCN are traded under the ticker "SCN" on Oslo Axess (www.osloaxess.no) and NGM Equity (www.ngm.se). For more information, please visit www.scnutrition.com.